| [1] PubMed ID: | 30210701 |
| Disease Name: | Pancreatic Neoplasms |
| Sample: | PC tissues and serums |
| Dysfunction Pattern: | Expression[highly expressed] |
| Validated Method: | qRT-PCR//MTT |
| Description: | The results showed that LINC00346, LINC00578, and LINC00673 were highly expressed, whereas LINC00671, LINC00261, and SNHG9 were lowly expressed in PC tissues and serums, and their expression levels were correlated with clinical stages. |
| Causality: | Yes |
| Causal Description: | In addition, we also found that silence of LINC00346, LINC00578 and LINC00673 inhibited PC cell proliferation, and silence of LINC00671, LINC00261, and SNHG9 promoted PC cell proliferation. |
| Clinical-realted Application: | Survival analysis indicated that patients with high expression of LINC00346, LINC00578, or LINC00673 had significantly lower survival rate, while patients with high expression of LINC00671, LINC00261, and SNHG9 had significantly higher survival rate. |
| [2] PubMed ID: | 30728036 |
| Disease Name: | Pancreatic Neoplasms |
| Sample: | |
| Dysfunction Pattern: | Interaction[sponging miR-188-3p to derepress BRD4] |
| Validated Method: | Western Blot//qRT-PCR//RIP//FISH//MTT//Luciferase Report Assay//Colony Formation Assay |
| Description: | LINC00346 shows the ability to promote pancreatic cancer growth and gemcitabine resistance, which is in part mediated by antagonization of miR-188-3p and induction of BRD4. Targeting LINC00346 may improve gemcitabine-based therapeutic efficacy. |
| Causality: | Yes |
| Causal Description: | Overexpression of LINC00346 significantly enhanced the proliferation, colony formation, and tumorigenesis of pancreatic cancer cells. Conversely, knockdown of LINC00346 suppressed pancreatic cancer cell proliferation and caused a cell-cycle arrest at the G2/M-phase. |
| Clinical-realted Application: | |
|